These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 27062282)
21. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma. Mehta A; Forero-Torres A Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424 [TBL] [Abstract][Full Text] [Related]
22. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686 [TBL] [Abstract][Full Text] [Related]
25. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Wang J; Press OW; Lindgren CG; Greenberg P; Riddell S; Qian X; Laugen C; Raubitschek A; Forman SJ; Jensen MC Mol Ther; 2004 Apr; 9(4):577-86. PubMed ID: 15093188 [TBL] [Abstract][Full Text] [Related]
26. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160 [TBL] [Abstract][Full Text] [Related]
27. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282 [TBL] [Abstract][Full Text] [Related]
28. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. van Meerten T; Hagenbeek A Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518 [TBL] [Abstract][Full Text] [Related]
30. Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done? Witkowska M; Smolewski P; Majchrzak A; Robak T Expert Opin Drug Discov; 2016 Nov; 11(11):1033-1045. PubMed ID: 27569454 [TBL] [Abstract][Full Text] [Related]
31. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535 [TBL] [Abstract][Full Text] [Related]
32. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Barth MJ; Minard-Colin V Br J Haematol; 2019 Jun; 185(6):1111-1124. PubMed ID: 30701541 [TBL] [Abstract][Full Text] [Related]
33. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996 [TBL] [Abstract][Full Text] [Related]
34. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Collins-Burow B; Santos ES Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647 [TBL] [Abstract][Full Text] [Related]
35. Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma. Singh F; Weinberg JM Cutis; 2005 Sep; 76(3):186-8. PubMed ID: 16268262 [TBL] [Abstract][Full Text] [Related]
36. [Auto-immune manifestations in Non-Hodgkin's lymphoma]. Jardin F; Lévesque H; Tilly H Rev Med Interne; 2005 Jul; 26(7):557-71. PubMed ID: 15996570 [TBL] [Abstract][Full Text] [Related]